<DOC>
	<DOCNO>NCT03025958</DOCNO>
	<brief_summary>Radiation Plus Concurrent Nimotuzumab Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_summary>
	<brief_title>Radiation Plus Concurrent Nimotuzumab Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Elderly patient locoregionally advanced nasopharyngeal carcinoma give initial dose nimotuzumab ( 200 mg ) 7days receive concurrent radiotherapy , weekly nimotuzumab ( 200 mg/week ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Previously untreated histologically confirm locoregionally advanced nasopharyngeal carcinoma A history another invasive cancer , prior RT head neck area , prior cytotoxic chemotherapy antiEGFR therapy presence serious medical condition , suppose live less 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>